Designing Paclitaxel Drug Delivery Systems Aimed at Improved  Patient Outcomes: Current Status and Challenges

<table>Mean plasma concentration of paclitaxel after IV administration of paclitaxel injection (▪) and paclitaxel microemulsion (○) in rats (<svg height="11.1" id="M1" style="vertical-align:-0.17555pt" version="1.1" viewbox="0 0 35.099998 11.1" width="35.099998" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,11.1)">
<g transform="translate(72,-63.12)">
<text transform="matrix(1,0,0,-1,-71.95,63.35)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑛</tspan>
<tspan style="font-size: 12.50px; " x="9.6773224" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="21.71771" y="0">5</tspan>
</text>
</g>
</g>
</svg>) (reproduced with permission from He et al. [<a href="/journals/isrn/2012/623139/#B9">9</a>]). </table>

International Scholarly Research Notices

fig13

Figure 13

Figure 13: Designing Paclitaxel Drug Delivery Systems Aimed at Improved  Patient Outcomes: Current Status and Challenges 